Skip to main content

Table 4 Clinical relevance of four variants among trauma patients

From: Identification of haplotype tag single nucleotide polymorphisms within the receptor for advanced glycation end products gene and their clinical relevance in patients with major trauma

 

Polymorphic sites

Genotypes

N

Age (yr)

Sex (M/F)

ISS

Sepsis, n/%

MOD score

Chongqing

 

ins/ins

423

40.2 ± 14.6

334/89

22.3 ± 10.5

178 (42.1)

6.4 ± 2.4

 

63 bp ins/del

ins/del

70

40.9 ± 11.1

59/11

20.5 ± 10.5

23 (32.9)

6.1 ± 2.8

  

del/del

3

47.3 ± 18.8

2/1

24.3 ± 8.5

1 (33.3)

6.0 ± 1.7

  

GG

247

39.5 ± 14.4

198/49

22.2 ± 11.4

100 (40.5)

6.7 ± 2.6

 

rs2070600

GA

206

41.0 ± 14.4

161/45

21.9 ± 9.4

84 (40.8)

6.1 ± 2.3

  

AA

43

42.5 ± 11.5

36/7

22.0 ± 10.4

18 (41.9)

5.7 ± 1.6

  

TT

364

40.4 ± 14.3

291/73

22.2 ± 10.4

148 (40.7)

6.3 ± 2.4

 

rs1800624

TA

117

40.5 ± 14.3

91/26

21.7 ± 11.0

51 (43.6)

6.5 ± 2.5

  

AA

15

39.7 ± 12.0

13/2

20.2 ± 8.8

3 (20.0)

7.0 ± 2.6

  

TT

365

40.0 ± 14.1

291/74

22.4 ± 10.5

163 (44.7)

6.9 ± 2.4

 

rs1800625

TC

116

42.4 ± 14.4

89/27

21.3 ± 10.7

35 (30.2)

6.0 ± 2.2

  

CC

15

37.3 ± 9.9

15/0

17.2 ± 9.8

4 (26.7)

5.3 ± 1.5

       

a1

a2, b1, c1

Zhejiang

 

ins/ins

203

41.0 ± 12.9

165/38

23.3 ± 8.6

74 (36.4)

6.9 ± 3.4

 

63bp ins/del

ins/del

29

41.1 ± 14.9

25/4

22.7 ± 9.3

14 (48.3)

8.4 ± 3.0

  

del/del

0

-

-

-

0 (0)

-

  

GG

126

41.3 ± 13.4

102/24

22.7 ± 8.6

48 (38.1)

7.1 ± 3.1

 

rs2070600

GA

85

40.7 ± 12.4

70/15

23.0 ± 8.5

35 (41.2)

6.9 ± 3.6

  

AA

21

40.6 ± 14.5

18/3

27.5 ± 8.6

5 (23.8)

6.9 ± 2.8

 

rs1800624

TT

181

41.0 ± 13.3

150/31

23.4 ± 8.7

70 (38.7.)

7.0 ± 3.5

  

TA

48

40.6 ± 13.0

38/10

22.4 ± 8.3

16 (33.3)

7.4 ± 3.2

  

AA

3

44.7 ± 7.1

2/1

28.0 ± 14.1

2 (67.7)

6.7 ± 2.3

  

TT

163

41.4 ± 13.2

138/25

23.7 ± 8.5

70 (42.9)

7.3 ± 3.3

 

rs1800625

TC

64

40.9 ± 13.2

47/17

21.8 ± 8.6

16 (25.0)

6.9 ± 3.2

  

CC

5

37.7 ± 15.7

4/1

24.3 ± 12.0

2 (40.0)

6.3 ± 2.5

       

a3

a4, c2

  1. A, dominant effect (variant homozygotes +heterozygotes vs. wild homozygotes) as analyzed by ANOVA, a1P = 0.003, a2P = 0.015, a3P = 0.016, a4P = 0.042; b, recessive effect (variant homozygotes vs. heterozygotes + wild homozygotes); as analyzed by ANOVA, b1P = 0.032; c, Allele Dose Effect as analyzed by linear regression, c1P = 0.045, c2P = 0.048.